Search Results - "Chirovsky, D"

From Clinical Trials to Real-World Practice: Surgical Feasibility and Postoperative Outcomes After Neoadjuvant Chemoimmunotherapy for Locally Advanced NSCLC in a Single-Center Experience.

Authors: Lococo, Filippo Nachira, Dania Kuzmych, Khrystyna et al.

Source: Cancers. Jun2026, Vol. 18 Issue 12, p1914. 15p.

Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer †.

Authors: Leuzzi, Giovanni Sabia, Federica Calderoni, Matteo et al.

Source: Cancers. Feb2026, Vol. 18 Issue 3, p367. 14p.

Exploring the Therapeutic Potential of Nobiletin in Nonsmall Cell Lung Cancer.

Authors: Haysom-McDowell, Adam Bartholomew, Jack Yeung, Stewart et al.

Source: BioMed Research International. 6/26/2026, Vol. 2026, p1-17. 17p.

Real-World Outcomes of First-Line Cetuximab and Platinum-Based Chemotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter Observational Study and Literature Review.

Authors: Rakušić, Zoran Bišof, Vesna Vušković, Sanja et al.

Source: Current Oncology. Apr2026, Vol. 33 Issue 4, p183. 14p.

Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study.

Authors: Delmonte, Angelo Gentili, Nicola Roncadori, Andrea et al.

Source: Cancers. Feb2026, Vol. 18 Issue 3, p538. 23p.

Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer.

Authors: Liu, Jing Lan, Chunyan Liu, Tongyu et al.

Source: BMC Medicine. 7/1/2025, Vol. 23 Issue 1, p1-10. 10p.

First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis.

Authors: Li, Huijuan Liang, Xueyan Qin, Shiran et al.

Source: PLoS ONE. 5/16/2025, Vol. 20 Issue 5, p1-12. 12p.

Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors.

Authors: Halmos B Rai P Min J et al.

Source: Frontiers in oncology [Front Oncol] 2024 Apr 18; Vol. 14, pp. 1285280. Date of Electronic Publication: 2024 Apr 18 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

The Prognostic Potential of PD-L1, PD-1, CD3, CD4, and CD8 Expression in Patients with Head and Neck Cancers Depending on HPV16 Infection.

Authors: Mucha-Małecka, Anna Biesaga, Beata Amrogowicz, Natalia et al.

Source: Cancers. Jun2026, Vol. 18 Issue 11, p1771. 19p.

Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era.

Authors: Theriau, Christopher F. Li, Yuchen Akurang, Deborah et al.

Source: Current Oncology. May2026, Vol. 33 Issue 5, p277. 18p.

The Impact of Body Composition on Outcomes in NSCLC Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review.

Authors: Golban, Carina Susa, Septimiu-Radu Varga, Norberth-Istvan et al.

Source: Cancers. Sep2025, Vol. 17 Issue 17, p2765. 29p.

MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K/AKT/mTOR signaling pathway.

Authors: Guan, Rui Li, Ce Jiao, Ruijie et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 7/26/2025, Vol. 44 Issue 1, p1-21. 21p.

Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study.

Authors: Renaud, Stéphane Casabianca, Paul Diez-Andreu, Pauline et al.

Source: BMC Cancer. 5/30/2025, Vol. 25 Issue 1, p1-11. 11p.

Head and neck squamous cell carcinoma-derived extracellular vesicles mediate Ca²⁺-dependent platelet activation and aggregation through tissue factor.

Authors: Weiser, Tobias Hoch, Cosima C. Petry, Julie et al.

Source: Cell Communication & Signaling. 5/1/2025, Vol. 23 Issue 1, p1-18. 18p.

Diagnosis of locally recurrent head and neck squamous cell carcinoma in the Nordic HNC centers and feasibility of the Odense-Birmingham definition.

Authors: Rohde, Max Eriksen, Jesper Grau Pareek, Manan et al.

Source: Acta Oncologica. Sep2023, Vol. 62 Issue 9, p1102-1105. 4p. 2 Charts.

Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.

Authors: West H Hu X Zhang S et al.

Source: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2023 Jul; Vol. 29 (7), pp. 749-757.

Publication Type: Observational Study; Journal Article

Journal Info: Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE

Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy.

Authors: Donington J Hu X Zhang S et al.

Source: The Journal of thoracic and cardiovascular surgery [J Thorac Cardiovasc Surg] 2024 Oct; Vol. 168 (4), pp. 1261-1269.e1. Date of Electronic Publication: 2023 Dec 12.

Publication Type: Journal Article

Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 0376343 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-685X (Electronic) Linking ISSN: 00225223 NLM ISO Abbreviation: J Thorac Cardiovasc Surg Subsets: MEDLINE

Outcomes of Resectable Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy: A Single Institution Experience.

Authors: Noy, Jose Chang, Alexander Chow, Nelly P. et al.

Source: Journal of Clinical Medicine. Feb2025, Vol. 14 Issue 3, p988. 14p.

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).

Authors: Grünwald V Alt J Tometten M et al.

Source: British journal of cancer [Br J Cancer] 2026 Jul 18. Date of Electronic Publication: 2026 Jul 18.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer.

Authors: Shalata, Walid Daher, Sameh Maimon Rabinovitch, Natali et al.

Source: Journal of Clinical Medicine. Nov2024, Vol. 13 Issue 21, p6568. 13p.